Participants 352 476 4
patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy
Participants 478 580 4
Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
Participants 868 965 4
1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy
Participants 1933 2053 4
 of patients with metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemothe
Participants 2114 2148 3
 in patients with squamous cell tu
Participants 2230 2349 3
 in patients with tumors harboring epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrat
